All In Biotech

Drug Trial Radar · NCT05777993

A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

55

Planned (sponsor's estimate)

Start

Jul 6, 2023

Primary completion

Aug 2029

Study completion Aug 2031

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to provide continued access to participants who are deriving clinical benefit from ongoing mitapivat treatment in an Agios-sponsored mitapivat study, in the opinion of the Investigator.

Conditions

  • Pyruvate Kinase Deficiency
  • Anemia, Hemolytic
  • Sickle Cell Disease
  • Thalassemia

Interventions

  • MitapivatDrug

    Tablets, granules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Not applicable as this protocol is to provide an option for continued access to mitapivat for participants who have previously participated in an Agios-sponsored mitapivat studyTime frame: Not Applicable - Study Completion

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • Hôpital Erasme

    Anderlecht, Brussels Capital, Belgium

  • HEMORIO Instituto Nacional de Hematologia

    Rio de Janeiro, Brazil

  • Praxis Pesquisa Medica

    Santo André, Brazil

  • GSH Banco de Sangue de São Paulo

    São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo

    São Paulo, Brazil

  • Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP

    São Paulo, Brazil

  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas da Unicamp

    Campinas, São Paulo, Brazil

  • McMaster Centre for Transfusion Medicine McMaster University

    Hamilton, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • CHU de Bordeaux - Hôpital Pellegrin

    Bordeau, France

  • CHU Hôpital Henri Mondor

    Créteil, France

  • Hopital Edouard Herriot, CHU de Lyon

    Lyon, France

  • AP-HP - Hôpital Européen Georges Pompidou

    Paris, France

  • Hôpital Necker Enfants Malades

    Paris, France

  • Hopitaux de La Timone

    Marseille, Bouches-du-Rhône, France

  • Rambam Medical Center

    Haifa, Ḥeifā, Israel

  • Ziv Medical Center

    Safed, Ḥeifā, Israel

  • Kyoto Katsura Hospital

    Kyoto, Japan

  • Toho University - Omori Medical Center

    Ōta-ku, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Acibadem Adana Hospital

    Seyhan, Adana, Turkey (Türkiye)

  • Manchester Royal Infirmary, Manchester University NHS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.